Clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis—Sionna Therapeutics (SION) priced its upsized initial public offering of ...
The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Indusind Bank stock price went up today, 06 Feb 2025, by 0.45 %. The stock closed at 1060.70 per share. The stock is currently trading at 1065.50 per share. Investors should monitor Indusind Bank ...
Nifty 50 Today Live Updates on February 6, 2025: At 15:30 Nifty 50 was trading at 23595.70 (-0.42%). Today Nifty 50 has been ...
US private equity firm Riverwood Capital is buying Quicklizard for NIS 186 million, reflecting a 30% premium on yesterday's ...
If PH-ILD studies translate into the real world, the market opportunity for Liquidia is enormous. Where should we expect LQDA stock to be in the next few months? Find out.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback